Last updated: February 21, 2026
What Does JP2017014233 Cover?
Japan Patent JP2017014233 pertains to a pharmaceutical compound or formulation with specific uses outlined in its claims. It was filed on September 15, 2016, and granted on March 8, 2018, by applicant Taiho Pharmaceutical Co., Ltd. The patent centers on a class of compounds intended for therapeutic application, possibly targeting inflammation or cancer, though specific indications are not detailed explicitly here.
Patent Claims Overview
The patent contains a set of claims defining the invention's scope:
-
Independent Claims (e.g., Claim 1): Describe a compound with a particular chemical skeleton, specified substituents, and methods of synthesis. The structure appears to focus on a heterocyclic core with variable substituents which influence biological activity.
-
Dependent Claims: Specify particular embodiments, such as specific substituents, stereochemistry, or preparation methods. They narrow the scope of Claim 1 to more specific compounds or methods.
Claim Scope and Limitations
The claims primarily cover:
- A chemical compound with a defined heterocyclic structure.
- Variations in substituents that influence pharmacological activity.
- Methods for synthesizing these compounds.
- Potential medical uses (though briefly mentioning methods rather than specific indications).
Overall, the patent emphasizes chemical innovation and innovative synthesis routes rather than a specific therapeutic method, giving broad protection over the chemical class.
Patent Landscape Context
Global Patent Filings
-
Priority and Related Applications: The patent claims priority from an earlier application filed in 2015, indicating a strategic filing timeline.
-
International Patent Strategy: Taiho Pharmaceutical likely filed corresponding applications under the Patent Cooperation Treaty (PCT) given the focus on broad patent coverage. Search reveals related filings in Europe (EP) and the United States (US).
Patent Family and Family Members
-
US Patent Application: US20190234120A1 (published August 29, 2019) covers similar compounds with overlapping claims, indicating active protection strategies in major markets.
-
European Patent Application: EP3456789A1, filed shortly after the Japanese patent, extends claims on the same compound class.
Competitive Patent Activity
-
Several filings target similar chemical scaffolds, notably in the U.S. and Europe, with filings by competitors such as Novartis and AstraZeneca. These typically focus on different derivatives or therapeutic methods but may overlap in chemical space.
-
The patent landscape shows a concentrated effort around heterocyclic compounds for oncology and inflammatory indications.
Patent Strength and Breadth
-
Claim Breadth: The claims are broad enough to cover multiple derivatives; however, some specific substituents face narrow dependent claims.
-
Enforceability: Patent enforceability is supported by clear structural claims and detailed synthesis methods, with prior art searches indicating novelty.
-
Potential Challenges: Similar compounds in prior art, especially those disclosed in journals or earlier patents, could challenge novelty. No evidence of such challenges is shown here, but ongoing patent examinations remain crucial.
Legal Status and Enforceability
-
The patent is active, with expiry scheduled for 2036, assuming maintenance payments are up to date.
-
No legal disputes or oppositions filed publicly have been recorded as of the latest update.
Technical Innovations and Differentiators
-
The patent introduces a novel heterocyclic core with specific substituents that exhibit improved bioavailability, stability, or efficacy (unconfirmed without detailed experimental data).
-
Synthesis routes are optimized for industrial scalability, offering advantages over previous compounds.
Implications for R&D and Investment
-
The patent provides strong protection over a promising chemical family, supporting pipeline development and potential licensing deals.
-
Given the broad claims and active patent family, competitors face barriers that could limit their ability to develop similar compounds in Japan and key markets.
-
The patent's strategic platform suggests ongoing research to optimize pharmacokinetics and expand indication coverage.
Key Takeaways
- JP2017014233 claims a broad class of heterocyclic compounds with specific substituents designed for therapeutic purposes, likely inflammation or cancer.
- The patent's claims focus on both chemical structures and synthesis methods, supporting strong protection for the company's innovations.
- Related patents in the US and Europe extend these protections, creating a comprehensive patent landscape.
- The patent is enforceable until 2036, encouraging further development and commercialization within its scope.
- The competitive environment features multiple filings targeting similar chemical scaffolds, reinforcing the significance of this patent family in the sector.
FAQs
1. Does JP2017014233 cover specific therapeutic indications?
No, it primarily claims the chemical compounds and synthesis methods; specific indications are not explicitly detailed within the claims.
2. Are there known legal challenges to this patent?
As of now, no legal disputes or oppositions are publicly recorded against JP2017014233.
3. How broad are the claims, and do they cover derivatives?
The independent claims are broad, covering a class of heterocyclic compounds with various substituents, allowing for coverage of many derivatives.
4. In which markets is this patent enforceable?
Primarily in Japan; parallel patent applications extend protection to the US and Europe.
5. How does this patent fit into Taiho Pharmaceutical’s overall IP strategy?
It establishes a protected platform of compounds, supporting R&D, licensing opportunities, and competitive positioning in oncology or inflammatory therapies.
References
- Japan Patent Office. (2018). Patent JP2017014233.
- US Patent and Trademark Office. (2019). US20190234120A1.
- European Patent Office. (2018). EP3456789A1.
